BAY 12-9566

BAY 12-9566

A novel inhibitor of matrix metalloproteinases with antiangiogenic activity, which made it to phase-III trials for managing advanced pancreatic cancer but proved inferior to gemcitabine (4-month survival vs 7-month survival, respectively), the agent against which is was being compared, and subsequently has been abandoned.
Segen's Medical Dictionary. © 2012 Farlex, Inc. All rights reserved.